Abstract: PUB421
Mycophenolate Sodium in Primary Membranous Nephropathy: A Retrospective Analysis
Session Information
Category: CKD (Non-Dialysis)
- 2102 CKD (Non-Dialysis): Clinical, Outcomes, and Trials
Author
- Raju, Sree Bhushan, Shiloh House, Hyderabad, TELANGANA, India
Background
We studied the efficacy and safety of mycophenolate sodium (MMS) in primary membraneous nephropathy (MN)
Methods
A Retrospective observational study of 58 cases of treatment naïve MN. Patients were given prednisolone (20mg/day tapered to 5mg/day by 3 months) along with MMS (2 tablets of 360mg twice-a-day) and changes in eGFR and proteinuria from baseline to the end of one year were noted.
Results
A total 44 cases were included in analysis.There is no significant worsening of s.creatinine (0.85± 0.17 mg/dl v/s 0.95± 0.30 mg/dl, p=0.23) or eGFR (105.97 ± 19.10 v/s 97.18 ±20.35 ml/min/1.73m2,P= 0.33). There is an improvement in s. albumin levels (2.17± 0.62 v/s 2.78± 0.59 gm/dl, p=0.001) and urinary protein levels (6811.36 ±1654.50 v/s 3360.34 ±2270.54 gm/day, p=0.001). At 12 months, partial response (PR) was seen in 29.54%, complete response (CR) in 20.45% and no response in 50%. The mean time to attain PR was 9.47± 1.8 mon and for for CR, 10.33 ± 1.5 mon. PLAR 2 positive cases had significantly earlier PR. The common complications were hypertension (18%) and diarrhoea (11%).
Conclusion
A 12-month course of MMS decreased proteinuria and improved renal function in patients with MN with less side effects.